Dr Zheng-gang Ren, Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, China. Email: [email protected]

Search for more papers by this author

Rong-xin Chen,

Rong-xin Chen

Liver Cancer Institute, Zhongshan Hospital

Search for more papers by this author

Yu-hong Gan,

Yu-hong Gan

Liver Cancer Institute, Zhongshan Hospital

Search for more papers by this author

Ning-lin Ge,

Ning-lin Ge

Liver Cancer Institute, Zhongshan Hospital

Search for more papers by this author

Yi Chen,

Yi Chen

Liver Cancer Institute, Zhongshan Hospital

Search for more papers by this author

Hui Ma,

Hui Ma

Liver Cancer Institute, Zhongshan Hospital

Search for more papers by this author

Yan Wang,

Yan Wang

Liver Cancer Institute, Zhongshan Hospital

Search for more papers by this author

Bo-heng Zhang,

Bo-heng Zhang

Liver Cancer Institute, Zhongshan Hospital

Search for more papers by this author

Yan-hong Wang,

Yan-hong Wang

Liver Cancer Institute, Zhongshan Hospital

Search for more papers by this author

Sheng-long Ye,

Sheng-long Ye

Liver Cancer Institute, Zhongshan Hospital

Search for more papers by this author

Jian-feng Luo,

Jian-feng Luo

Department of Health Statistics and Social Medicine, School of Public Health, Fudan University, Shanghai, China

Search for more papers by this author

Zheng-gang Ren,

Corresponding Author

Zheng-gang Ren

Liver Cancer Institute, Zhongshan Hospital

Correspondence

Dr Zheng-gang Ren, Liver Cancer Institute, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, China. Email: [email protected]

Search for more papers by this author

First published: 11 August 2015

https://doi.org/10.1111/jgh.13077

Citations: 14

Declaration of conflict of interest:

None.

Share a link

Email
Wechat
Bluesky

Abstract

Background and Aim:

Radiofrequency ablation (RFA) is recommended as one of the standard treatments for early hepatocellular carcinoma (HCC). Because of high-risk tumor locations unfit for RFA, transarterial chemoembolization (TACE) is served as an alternative option in these settings. To define the role of TACE on early HCC, we retrospectively compared the efficacies of TACE with RFA in patients with unresectable Barcelona Clinic Liver Cancer (BCLC) stage 0/A HCC.

Materials and Methods:

Treatment-naïve patients with unresectable BCLC stage 0/A HCC who underwent TACE or RFA were recruited from 2007 to 2011. In all, 208 patients who underwent TACE and 235 patients who underwent RFA were included in the final analysis. Using the propensity model to correct selection bias, 103 patients were selected from each treatment arm. Cumulative overall survival (OS) as the primary end point was compared after adjustment with propensity score matching.

Results:

In all patients, the OS rate was significantly higher in patients treated with RFA than that in those who received TACE (1-, 3-, and 5-year OS rates, 93.7%, 72.6%, and 58.1% vs 88.1%, 50.3%, and 30.4%, respectively; P < 0.001). However, adjustment with propensity score matching yielded comparable OS between the two groups (P = 0.207). Subgroup analysis showed that RFA provided better OS than TACE in patients with serum γ-glutamyltranspeptidase < 75 IU/L (P = 0.035). Univariate and subsequent multivariate analyses revealed that Child-Pugh class B (hazard ratio = 1.805; 95% confidence interval, 1.805–3.003; P = 0.023) and hepatitis C virus positivity (hazard ratio = 2.478; 95% confidence interval, 1.136–5.404; P = 0.023) were independent predictors of poor prognosis.

Conclusion:

Transarterial chemoembolization is an effective alternative treatment for unresectable BCLC stage 0/A HCC when RFA is not feasible.

Supporting Information

References

1Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69–90.
10.3322/caac.20107
PubMed Web of Science® Google Scholar
2Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–36.
10.1002/hep.20933
CAS PubMed Web of Science® Google Scholar
3Feng K, Yan J, Li X et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J. Hepatol. 2012; 57: 794–802.
10.1016/j.jhep.2012.05.007
PubMed Web of Science® Google Scholar
4Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734–9.
10.1016/S0140-6736(02)08649-X
PubMed Web of Science® Google Scholar
5Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164–71.
10.1053/jhep.2002.33156
CAS PubMed Web of Science® Google Scholar
6Lee HS, Kim KM, Yoon JH et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J. Clin. Oncol. 2002; 20: 4459–65.
10.1200/JCO.2002.02.013
PubMed Web of Science® Google Scholar
7Kim JW, Kim JH, Sung KB et al. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller. Am. J. Gastroenterol. 2014; 109: 1234–40.
10.1038/ajg.2014.152
PubMed Web of Science® Google Scholar
8Bargellini I, Sacco R, Bozzi E et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur. J. Radiol. 2012; 81: 1173–8.
10.1016/j.ejrad.2011.03.046
PubMed Web of Science® Google Scholar
9Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann. Surg. Oncol. 2014; 21: 3069–76.
10.1245/s10434-014-3704-8
PubMed Web of Science® Google Scholar
10Kim HC, Suk KT, Kim DJ et al. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J. Gastroenterol. 2014; 20: 745–54.
10.3748/wjg.v20.i3.745
PubMed Web of Science® Google Scholar
11Liem MS, Poon RT, Lo CM, Tso WK, Fan ST. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J. Gastroenterol. 2005; 11: 4465–71.
10.3748/wjg.v11.i29.4465
PubMed Web of Science® Google Scholar
12Yang HJ, Lee JH, Lee DH et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology 2014; 271: 909–18.
10.1148/radiol.13131760
PubMed Web of Science® Google Scholar
13Wang Y, Chen Y, Ge N et al. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann. Surg. Oncol. 2012; 19: 3540–6.
10.1245/s10434-012-2368-5
PubMed Web of Science® Google Scholar
14Yang B, Zou J, Xia J et al. Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation. Eur. J. Radiol. 2011; 79: 196–200.
10.1016/j.ejrad.2010.02.010
PubMed Web of Science® Google Scholar
15Brown DB, Nikolic B, Covey AM et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J. Vasc. Interv. Radiol. 2012; 23: 287–94.
10.1016/j.jvir.2011.11.029
PubMed Web of Science® Google Scholar
16Ju MJ, Tu GW, Han Y et al. Effect of admission time on mortality in an intensive care unit in Mainland China: a propensity score matching analysis. Crit. Care 2013; 17: R230.
10.1186/cc13053
PubMed Web of Science® Google Scholar
17Kim JW, Kim JH, Sung KB et al. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller. Am. J. Gastroenterol. 2014; 109: 1234–40.
10.1038/ajg.2014.152
PubMed Web of Science® Google Scholar
18Hsu KF, Chu CH, Chan DC et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur. J. Radiol. 2012; 81: 466–71.
10.1016/j.ejrad.2010.12.058
PubMed Web of Science® Google Scholar
19Song YG, Shin SW, Cho SK et al. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients. Acta Radiol. 2015; 56: 70–7.
10.1177/0284185114520857
CAS PubMed Web of Science® Google Scholar
20Hsu CY, Huang YH, Chiou YY et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl. 2011; 17: 556–66.
10.1002/lt.22273
PubMed Web of Science® Google Scholar
21Kim JH, Won HJ, Shin YM et al. Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann. Surg. Oncol. 2011; 18: 1624–9.
10.1245/s10434-011-1673-8
PubMed Web of Science® Google Scholar
22Matsui O, Kadoya M, Yoshikawa J et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188: 79–83.
10.1148/radiology.188.1.8390073
CAS PubMed Web of Science® Google Scholar
23Abbas Z, Siddiqui AU, Luck NH et al. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. J. Pak. Med. Assoc. 2008; 58: 602–7.
PubMed Google Scholar
24Izumi N, Asahina Y, Noguchi O et al. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer 2001; 91: 949–56.
10.1002/1097-0142(20010301)91:5<949::AID-CNCR1084>3.0.CO;2-H
CAS PubMed Web of Science® Google Scholar
25Shiina S, Tateishi R, Arano T et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am. J. Gastroenterol. 2012; 107: 569–77.
10.1038/ajg.2011.425
CAS PubMed Web of Science® Google Scholar
26Kikuchi L, Menezes M, Chagas AL et al. Percutaneous radiofrequency ablation for early hepatocellular carcinoma: risk factors for survival. World J. Gastroenterol. 2014; 20: 1585–93.
10.3748/wjg.v20.i6.1585
PubMed Web of Science® Google Scholar
27Umeda Y, Matsuda H, Sadamori H, Matsukawa H, Yagi T, Fujiwara T. A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection. World J. Surg. 2011; 35: 170–7.
10.1007/s00268-010-0794-8
PubMed Web of Science® Google Scholar
28Lee DH, Lee JM, Lee JY, Kim SH, Han JK, Choi BI. Radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: long-term results and prognostic factors in 168 patients with cirrhosis. Cardiovasc. Intervent. Radiol. 2014; 37: 705–15.
10.1007/s00270-013-0708-x
PubMed Web of Science® Google Scholar
29Sato M, Tateishi R, Yasunaga H et al. Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J. Gastroenterol. 2012; 47: 1125–33.
10.1007/s00535-012-0569-0
PubMed Web of Science® Google Scholar

Citing Literature

Volume31, Issue2

February 2016

Pages 442-449

Filename	Description
jgh13077-sup-0001-Supplementary.docxWord 2007 document , 18.7 KB	Supporting info item
jgh13077-sup-0002-FigS1.docxWord 2007 document , 24.9 KB	Supporting info item
jgh13077-sup-0003-FigS2.tifTIFF image, 645.7 KB	Supporting info item
jgh13077-sup-0004-FigS3.tifTIFF image, 635.8 KB	Supporting info item
jgh13077-sup-0004-FigS4.tifTIFF image, 449.9 KB	Supporting info item

Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching

Abstract

Background and Aim:

Materials and Methods:

Results:

Conclusion:

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching

Abstract

Background and Aim:

Materials and Methods:

Results:

Conclusion:

Supporting Information

References

Citing Literature

References

Related

Information